Sanofi-aventis Japan Acquires Production and Sales Rights of Ancaron Antiarrhythmic Agent from Taisho Pharmaceutical.Tokyo, Japan, Oct 15, 2005 - (JCNN JCNN Japan Corporate News Network ) - Sanofi-aventis Japan announced on October 11 that it has acquired the rights to produce and sell Ancaron (amiodarone hydrochloride a·mi·o·da·rone hydrochloride n. A vasodilator for the heart used to control ventricular and supraventricular arrhythmias and to manage stenocardia. ), an antiarrhythmic agent, from Taisho Pharmaceutical. In the meantime Adv. 1. in the meantime - during the intervening time; "meanwhile I will not think about the problem"; "meantime he was attentive to his other interests"; "in the meantime the police were notified" meantime, meanwhile , Taisho Pharmaceutical and its subsidiary Taisho Toyama Pharmaceutical will continue to manufacture and sell the agent by signing a consignment contract with Sanofi-aventis Japan. Ancaron, which was first introduced to Japan in 1992, is currently marketed over 100 countries worldwide. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion